Results 271 to 280 of about 83,254 (357)

Systemic Treatment with the Janus Kinase Inhibitor Baricitinib in Ocular Chronic Graft-versus-Host Disease. [PDF]

Ophthalmol Sci
McManus T, Holtzman NG, Zhao A, Cousineau-Krieger C, Vitale S, FitzGibbon EJ, Payne D, Newgen J, Igbinosun C, Im AP, Peer C, Figg WD, Cowen EW, Mays JW, Pavletic S, Magone MT.   +15 more
europepmc   +1 more source

Comparative Efficacy of Janus Kinase Inhibitors (JAKis) for Ulcerative Colitis in Japanese Regional Healthcare Facilities: A Real-World Database Study [PDF]

Yuki Itoi, Yu Hashimoto, Takashige Masuo, Tomoyuki Masuda, Kyoko Marubashi, Atsuo Iwamoto, Masanori Sekiguchi, Kazuhiro Takahashi, Yuko Kimura, Yoko Hachisu, Shota Tomaru, Keigo Sato, Hirohito Tanaka, Hiroko Hosaka, Shiko Kuribayashi, Yoji Takeuchi, Toshio Uraoka   +16 more
openalex   +1 more source

Tissue Resident Memory Cells: Friend or Foe?

Immunology, EarlyView.
Tissue‐resident memory T cells (TRM cells) are specialised immune cells in barrier tissues like the lungs, skin and gut, providing rapid host defence and tumour surveillance. Their retention and differentiation are regulated by molecules such as CD69, CD103 and TGF‐β. Dysregulation of TRM cells can lead to chronic activation, driving conditions such as
Chidimma F. Chude, Jude E. Uzonna, Janilyn Arsenio   +2 more
wiley   +1 more source

Results from an open-label phase 2a study of cerdulatinib, a dual spleen tyrosine kinase/janus kinase inhibitor, in relapsed/refractory peripheral T-cell lymphoma. [PDF]

Leuk Lymphoma
Horwitz SM, Feldman TA, Ye JC, Khodadoust MS, Munoz J, Hamlin PA, Kim YH, Wilcox RA, Patel MR, Coffey G, Innes A, Betz A, Holland J, Guzman CB, Smith SM.   +14 more
europepmc   +1 more source

Signal Transducer and Activator of Transcription (STAT) Proteins Regulate Mucosal‐Associated Invariant T (MAIT) Cell Function

Immunology, EarlyView.
Integrated transcriptomic, proteomic and flow cytometry analyses reveal that STAT1 negatively regulates MAIT cell effector and glycolytic functions, while STAT3, STAT5 and HIF1α act as positive modulators. Targeting these pathways may offer new strategies to restore MAIT cell function in immune dysregulation and cancer.
Olivia J. Cheng, Eimear K. Ryan, Michael Bennett, Christy Clutter, Jackson G. Cacioppo, Jeffrey Aubé, Andy E. Hogan, Daniel T. Leung   +7 more
wiley   +1 more source

Preclinical and clinical evaluation of the Janus Kinase inhibitor ruxolitinib in multiple myeloma. [PDF]

Oncotarget
Del Dosso A, Tadevosyan E, Berenson JR.
europepmc   +1 more source

Safety and efficacy of nemolizumab for atopic dermatitis up to 2 years in open‐label extension study

Journal of the European Academy of Dermatology and Venereology, EarlyView.
This study evaluated long‐term safety and efficacy in patients with moderate‐to‐severe atopic dermatitis. Patients with and without previous nemolizumab experience received nemolizumab 30 mg Q4W plus TCS/TCI. Nemolizumab was well‐tolerated through 104 weeks with clinically meaningful improvements in disease signs and symptoms.
Matthias Augustin, Marie Tauber, Robert Sidbury, Jonathan I. Silverberg, Kim A. Papp, Diamant Thaçi, Marjolein S. De Bruin‐Weller, Adam Reich, Ketty Peris, Kirk Barber, Ryszard Galus, Andrzej Kaszuba, Matthew Zirwas, Walter K. Nahm, Gretel Trullenque, Laura Maintz, Sady Alpizar, Sang Wook Son, Vivian Laquer, Linda Stein Gold, Soo Yeon Cheong, Anna Ryzhkova, Agnes Drahos, Liliana Ulianov, Christophe Piketty   +24 more
wiley   +1 more source

Effectiveness and Safety of Ruxolitinib Cream 15 mg/g in Patients With Non‐Segmental Vitiligo: A Real‐Life Study

International Journal of Dermatology, EarlyView.
Mattia Cristallo, Ippolita Zaza, Michelina Francesca Daddato, Loredana Muolo, Francesco Pugliese, Alice D'Amico, Marco Casciaro, Sebastiano Gangemi, Eustachio Nettis   +8 more
wiley   +1 more source

Therapeutic advances in pruritus as a model of personalized medicine

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Recent advances in itch biology reveal that chronic pruritus arises from distinct neuroimmune pathways driven by cytokines, JAK, BTK and GPCRs. Targeted biologics and small molecule inhibitors such as dupilumab, nemolizumab, remibrutinib and JAK inhibitors precisely modulate these pathways, leading to a new era of personalized therapeutics in pruritus.
Kelsey Auyeung, Ramsey Kubofcik, Brian S. Kim   +2 more
wiley   +1 more source

Impact of Prior Biologic or Janus Kinase Inhibitor Therapy on Efficacy and Safety of Etrasimod in the ELEVATE UC 52 and ELEVATE UC 12 Trials. [PDF]

J Crohns Colitis
Vermeire S, Sands BE, Peyrin-Biroulet L, D'Haens GR, Panés J, Yarur AJ, Wolf DC, Ritter T, Schreiber S, Woolcott JC, Modesto I, Keating M, Shan K, Wu J, Chiorean MV, Baert F, Dubinsky MC, Goetsch M, Danese S, Feagan BG.   +19 more
europepmc   +1 more source